Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06917092 | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer(QLPPEC/GOG-003) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06860477 | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) | recruiting | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Apr 6, 2025 |
| clinicaltrials |
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911606 | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 45 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT05563467 | Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.(PEMBR-01) | recruiting | Phase 2 | 24 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06904573 | Probiotics in Advanced Urothelial Carcinoma(IMPROVE) | recruiting | Phase 2 | 222 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | recruiting | Phase 2 | 97 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05955170 | Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer(TUC-TOC) | recruiting | Phase 2 | 66 | Institut CurieOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06693323 | Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC | recruiting | Phase 2 | 34 | University of California, IrvineOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06896890 | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 32 | Inhatarget TherapeuticsINDUSTRY | 3 | Mar 26, 2025 | clinicaltrials |
| NCT05776524 | Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 46 | THERABIONIC INC.OTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT03899428 | Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | recruiting | Phase 2 | 30 | Humanity & Health Medical Group LimitedOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 60 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05332561 | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | recruiting | Phase 2 | 240 | German Cancer Research CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | recruiting | Phase 2 | 23 | Okayama UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06521866 | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer | recruiting | Phase 2 | 208 | Fudan UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06869473 | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.(AVEC-119) | recruiting | Phase 2 | 67 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06663098 | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).(CARRY-ON) | recruiting | Phase 2 | 142 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06870942 | Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06742892 | A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | recruiting | Phase 2 | 90 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05918328 | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | recruiting | Phase 2 | 610 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863506 | Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC | recruiting | Phase 2 | 78 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04777084 | The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06208462 | Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06851247 | GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06851299 | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06852287 | Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer(GOLD-HAIC) | recruiting | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04954781 | TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05010681 | Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer(RESPONSE) | recruiting | Phase 2 | 185 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05057845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06849167 | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC | recruiting | Phase 2 | 63 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06494943 | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC | recruiting | Phase 1 / Phase 2 | 27 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05281406 | Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | recruiting | Phase 2 | 50 | Goethe UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05992220 | Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion(ALERT-HCC) | recruiting | Phase 2 | 138 | Asan Medical CenterOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06818682 | Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial(RELAX) | recruiting | Phase 2 | 206 | Tata Memorial CentreOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06397235 | DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC | recruiting | Phase 2 | 130 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06812728 | Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients | recruiting | Phase 2 | 100 | Menoufia UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT06832904 | Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) | recruiting | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | recruiting | Phase 1 / Phase 2 | 24 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Apr 8, 2025source: clinicaltrials